Verve Therapeutics, Inc. (VERV) News
Filter VERV News Items
VERV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VERV News Highlights
- For VERV, its 30 day story count is now at 3.
- Over the past 14 days, the trend for VERV's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- GENE, DEC and NOV are the most mentioned tickers in articles about VERV.
Latest VERV News From Around the Web
Below are the latest news stories about VERVE THERAPEUTICS INC that investors may wish to consider to help them evaluate VERV as an investment opportunity.
Wall Street Analysts Believe Verve Therapeutics (VERV) Could Rally 260.31%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 260.3% in Verve Therapeutics (VERV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private PlacementBOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock at a public offering price of $10.00 per share, which includes 1,875,000 shares issued upon the exercise in full by the underwriters of their opt |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning! |
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private PlacementBOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and other offering |
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private PlacementBOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Verve. In addition, Verve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of it |
Does Verve Therapeutics (VERV) Have the Potential to Rally 260.31% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 260.3% in Verve Therapeutics (VERV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Why Verve Therapeutics Stock Crashed as Much as 30% This WeekShares of Verve Therapeutics (NASDAQ: VERV) sank as much as 30.7% this week, according to data from S&P Global Market Intelligence. Verve is trying to build cutting-edge, gene-editing tools to help people deal with cardiovascular disease. Specifically, it hopes to commercialize its Verve-101 tool to edit human genes in people with naturally high LDL cholesterol (the bad cholesterol), which is correlated with heart disease. |
Verve Therapeutics: Why Great Results Aren't EnoughThe company's twist on CRISPR appears to work as intended but that didn't stop this biotech's stock price from collapsing. |
After Its Stock Crashed 42% in 1 Day, Is Verve Therapeutics a Buy?Since reporting some early-stage clinical data from one of its gene editing programs on Nov. 12, share prices of Verve Therapeutics (NASDAQ: VERV) are down 42%. Verve's program for heterozygous familial hypercholesterolemia (HeFH), VERVE-101, is currently in its phase 1b clinical trials, and it's also the lead program in its pipeline -- and is in fact its only clinical-stage program. In theory, VERVE-101 is intended to permanently edit patients' genes such that their LDL-C cholesterol levels are reduced, thereby correcting the hereditary defect driving those levels higher. |
Heart Disease Breakthrough by Gene-Editor Verve Knocks Its Stock for a LoopData showed that a single infusion of Verve's genetic treatment led to drops of 40% to 55% in the “bad” LDL cholesterol. |